Sixty Degree Capital

Sixty Degree Capital is a venture firm with a thesis tilt toward life sciences and healthcare technology, with limited public detail on current fund size, stage discipline, and check sizes. Treat the firm as a Series A and B participant writing checks plausibly in the $2M to $8M range, with the depth to lead in tightly thesis-aligned companies. Healthcare exposure is genuine and runs across biotech, medical devices, diagnostics, and selectively digital health with clear commercial or scientific anchoring. Physician founders building biotech assets, devices with defined regulatory paths, diagnostics, or digital health with credible reimbursement clarity are the right profile. Founders building consumer wellness brands or pure software without healthcare anchoring should pitch elsewhere. Geographic posture is US-led with international deal capacity. The realistic entry path is a warm introduction from a co-investing healthcare specialist, a clinical advisor in the firm’s network, or an existing portfolio CEO; partners are accessible at JPM, BIO, and AdvaMed but prefer referred deals. Founders should arrive with KOL scientific support, defended IP, a clear regulatory plan, and an articulated commercial pathway. Treat Sixty Degree Capital as a healthcare-dedicated specialist that brings category fluency and operating insight, and a credible Series A or B partner for companies preparing for clinical pivotal studies, regulatory submissions, or initial commercial scaling.